CD274 and non-small cell lung carcinoma: As a conclusion, the metabolic score could provide clinicians an early indication of treatment failure in patients with PD-L1 TPS ≥ 50%, after the initiation of first-line pembrolizumab, using standard of care 18F-FDG PET scans and pre-treatment blood counts, which are both systematically performed in all advanced NSCLC patients before starting systemic therapies.